If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 2002 Ph.D. National Taiwan University
  • 1994 M.S. Taipei Medical University

Experience

  • 2020- Vice Dean, College of Medical Science and Technology, Taipei Medical University
  • 2019- Director, Ph.D. Program in Drug Discovery and Development Industry, Taipei Medical University
  • 2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University
  • 2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2008-2013 Assistant Professor, Department of Pharmacology, Taipei Medical University
  • 2009-2013 Assistant Investigator, National Health Research Institutes
  • 2007-2009 Assistant Investigator, National Taiwan University
  • 2002-2007 Postdoctor, National Taiwan Universiy
  • 1994-1998 Teaching Assistant, Chang-Gung University

Research Interests

  • Drug Discovery
  • Disease animal model
  • Pharmacology

URL

Awards

  • 2019 Single Research Project Budget Award, Taipei Medical University

Fingerprint Dive into the research topics where Shiow-Lin Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(3/3)

Pan, S.

8/1/207/1/21

Project: A - Government Institutionb - Ministry of Science and Technology

The Role of Protein Kinase CK1 and The Mechanism of Inhibitors on Glioblastoma Cells

Pan, S.

7/1/202/1/21

Project: A - Government Institutionb - Ministry of Science and Technology

以體內及體外試驗來進行SYRK1B抑制劑之毒理學評估

Pan, S.

1/1/2012/31/20

Project: A - Government Institutiond - Ministry of Education

Drug Discovery and Pharmacological Investigation of Novel Selective Hdac Inhibitors as Anticancer Drugs

Pan, S.

8/1/197/31/20

Project: A - Government Institutionb - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究(II)

Pan, S.

5/1/191/31/20

Project: A - Government Institutionb - Ministry of Science and Technology

Research Output

  • 3242 Citations
  • 34 h-Index
  • 137 Article
  • 5 Comment/debate

A site-moiety map and virtual screening approach for discovery of novel 5-LOX inhibitors

Hsu, K. C., HuangFu, W. C., Lin, T. E., Chao, M. W., Sung, T. Y., Chen, Y. Y., Pan, S. L., Lee, J. C., Tzou, S. C., Sun, C. M. & Yang, J. M., Dec 1 2020, In : Scientific Reports. 10, 1, 10510.

Research output: Contribution to journalArticle

Open Access
  • Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors

    Chang, F. L., Tsai, K. C., Lin, T. Y., Yang, T. W., Lo, Y. N., Chen, W. C., Chang, J. H., Lu, M. K., Chiou, C. T., Chen, P. H., Yen, Y., Pan, S. L. & Lee, Y. C., Jan 1 2020, In : BioMed Research International. 2020, 3415471.

    Research output: Contribution to journalArticle

    Open Access
  • 4 Citations (Scopus)

    Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells (Oncogenesis, (2017), 6, 7, (e359), 10.1038/oncsis.2017.61)

    Huang, H. L., Wu, H. Y., Chu, P. C., Lai, I. L., Huang, P. H., Kulp, S. K., Pan, S. L., Teng, C. M. & Chen, C. S., Feb 1 2020, In : Oncogenesis. 9, 2, 27.

    Research output: Contribution to journalComment/debate

    Open Access
  • Open Access
  • Open Access